American Gastroenterological Association (07/30/15)

A new member survey from the American Gastroenterological Association found that 91 percent of respondents said they prescribe biologic drugs to their patients with inflammatory bowel disease (IBD). The survey, which involved 180 respondents, also noted that 60 percent said they have had to change their patient's treatment due to insurance plans. The researchers noted that 40 percent of the respondents said they considered themselves extremely or very familiar with biosimilars, while 72 percent said they would likely prescribe biosimilars if they became available. Two-thirds of the respondents indicated they support a policy in which the Food and Drug Administration would not allow indication extrapolation in the approval of biosimilars for IBD.

Web Link 

Abstract News © 2015 INFORMATION, INC.

Access other Therapeutic Areas:


 

New & Noteworthy